AI assistant
Lifecare ASA — AGM Information 2024
Sep 3, 2024
3654_rns_2024-09-03_6f046eff-8e75-40d8-bdcc-e896af88d5f6.html
AGM Information
Open in viewerOpens in your device viewer
LIFECARE ASA: Extraordinary General Meeting
LIFECARE ASA: Extraordinary General Meeting
Lifecare ASA, a clinical stage medical sensor company developing the next
generation Continuous Glucose Monitor (CGM), will hold an Extraordinary
General Meeting 17 September 2024, at 09:00 (CEST).
For the planned uplisting from Euronext Growth Oslo to Oslo Børs, a share
consolidation is required to meet the NOK 10 per share listing requirement.
Additionally, to address shareholders with fractional shares
post-consolidation, the Board proposes General Meeting's approval to acquire
treasury shares.
The notice with complete agenda and documents is available on
https://lifecare.no/events/.
The meeting will be available here:
(https://teams.microsoft.com/l/meetup-join/19%3ameeting_MzRkYWIyMjItYTU2MC00MGMwLTk3NDEtNTE4ZTZlYTk2NzRh%40thread.v2/0?context={"Tid"%3a"c5fbb1c6-4eb0-45db-9f3c-6e20ebcd710e"%2c"Oid"%3a"71082610-7009-40ed-92e6-70ae6bc35450"})
https://teams.microsoft.com/l/meetup-join/19%3ameeting_MzRkYWIyMjItYTU2MC00MGMwLTk3NDEtNTE4ZTZlYTk2NzRh%40thread.v2/0?context=%7b%22Tid%22%3a%22c5fbb1c6-4eb0-45db-9f3c-6e20ebcd710e%22%2c%22Oid%22%3a%2271082610-7009-40ed-92e6-70ae6bc35450%22%7d
About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, [email protected], +47 40 05 90 40
Renete Kaarvik, CFO, [email protected], +47 94 83 82 42
This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2024-09-03 14:31 CEST.